Abstract: With the expansion of FDA approved ¹⁸F- and ⁶⁸Ga- based agents for medical imaging using positron emission tomography (PET), research into the production of isotopes with varying half-lives, chemistry and decay characteristics is expanding. Using the UAB TR24 cyclotron, our group has focused on the development of reaction routes, target materials and the separation chemistry of isotopes to expand the toolbox of nuclear imaging agents. These have included transition metals such as ⁵²Mn, ⁵⁵Co, ⁸⁹Zr, ^43,47Sc and ⁴⁵Ti. Additional research has developed chemistry to incorporate these isotopes into new imaging radiopharmaceuticals for preclinical or clinical research. In particular, our group has been exploring the use of ⁸⁹Zr radiolabeled antibodies for imaging of cell surface receptor expression in preclinical models and in clinical trials of metastatic breast cancer patients. Recent work has also resulted in new radiochemistry techniques for the development of new ^43,47Sc, ⁵⁵Co and ⁴⁵Ti radiopharmaceuticals for oncologic applications.